Difference between revisions of "Coronavirus studies"
(a start) |
(added recent study) |
||
| Line 16: | Line 16: | ||
Hydroxychloroquine appears to be effective against COVID-19 both as a prophylaxis and as early treatment.<ref>https://link.springer.com/content/pdf/10.1007/s40267-020-00741-x.pdf</ref> | Hydroxychloroquine appears to be effective against COVID-19 both as a prophylaxis and as early treatment.<ref>https://link.springer.com/content/pdf/10.1007/s40267-020-00741-x.pdf</ref> | ||
| + | |||
| + | == French study == | ||
| + | |||
| + | In a study of 3,737 COVID-19 patients, the researchers found that "Treatment with [[HCQ]]-AZ was associated with a decreased risk of transfer to ICU or death (Hazard ratio (HR) 0.18 0.11–0.27), decreased risk of hospitalization ≥10 days and shorter duration of viral shedding."<ref>https://www.sciencedirect.com/science/article/pii/S1477893920302817</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 23:34, June 25, 2020
Numerous coronavirus studies demonstrate the prophylactic and early use of hydroxychloroquine against COVID-19, which are being ignored or downplayed for political reasons.
Here is a sampling of the growing list of valid studies confirming the effectiveness of hydroxychloroquine against COVID-19:
Minnesota data mining study
The incidence rate and mortality from COVID-19 was found to be lower in patients on chronic hydroxychloroquine therapy, in a large Minnesota healthcare system.
Between April 1, 2019 and March 31, 2020, the database contained 1,271,014 unique patient encounters, including a total of 2945 COVID-19 tests, of which 125 (4.24%) were positive.
Among the tests performed, 124 (4.35%) were positive for COVID-19 while not having taken hydroxychloroquine, while 96 tests were performed in patients with existing hydroxychloroquine prescriptions and only one (1.04%) was positive.
Two COVID-19 patients not on hydroxychloroquine died, while no COVID-19 patients not on hydroxychloroquine died.
Hydroxychloroquine appears to be effective against COVID-19 both as a prophylaxis and as early treatment.[1]
French study
In a study of 3,737 COVID-19 patients, the researchers found that "Treatment with HCQ-AZ was associated with a decreased risk of transfer to ICU or death (Hazard ratio (HR) 0.18 0.11–0.27), decreased risk of hospitalization ≥10 days and shorter duration of viral shedding."[2]
References
| |||||||||||||||||||||||||||||||||||